Nanodrugs

USE OF A COMPOSITION COMPRISING A NEO-SYNTHESIZED EXTRACELLLAR MATRIX FOR THE TREATMENT OF CANCER, IN PARTICULAR FOR THE INHIBITION OF CANCER VIABILITY, MIGRATION, AND PROLIFERATION

Absstract of: WO2024175520A1

The present invention relates to the use of a composition comprising a neo-synthesized extracellular matrix for the treatment of cancer, in particular for the inhibition of cancer viability, migration and proliferation.

METHODS OF TREATING SEPSIS USING POLY(LACTIC ACID) NANOPARTICLES

Absstract of: WO2024178350A1

Methods of treating sepsis via administration of poly(lactic acid) (PLA) immunomodulatory nanoparticles (iNPs) are disclosed. Such methods can also be used to modulate an immune response in a subject having sepsis and promote an anti-inflammatory response in such subjects.

A method for reducing the risk of coronary disease

Absstract of: GB2627644A

Provided herein are methods of preparing formulations comprising GalNAc-lipid nanoparticles, especially formulations comprising a GalNAC-lipid receptor targeting conjugate as defined therein. Said formulations are useful for targeted delivery of therapeutic agents for modifying expression and function of target genes, e.g. proteins involved in lipid and cholesterol metabolism such as PCSK9.

BIOSOLUBLE POLYMER OR PARTICLE FOR DELIVERY OF AN ACTIVE AGENT AND A METHOD FOR THE PRODUCTION

Absstract of: CN118201638A

The invention relates to a method for producing a polymer in the form of a gel or a particle, and to the resulting polymer, gel and particle, respectively. The polymer comprises a carbon donor and a metal oxide precursor, a metal oxide, or a combination thereof, and optionally an active agent. The invention also relates to compositions and membranes comprising such polymers and their use as medicaments, for example in the treatment of diabetes, obesity, neuronal diseases, viral infections or cancer.

LIPIDS AND LIPID NANOPARTICLE FORMULATIONS FOR DELIVERY OF NUCLEIC ACIDS

Absstract of: EP4420679A2

Compounds are provided having the following structure:or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein R^1a, R^1b, R^2a, R^2b , R^3a , R^3b, R^4a, R^4b, R⁵, R⁶, R⁷, R⁸, R⁹, L¹, L², G¹, G², G³, a, b, c and d are as defined herein. Use of the compounds as a component of lipid nanoparticle formulations for delivery of a therapeutic agent, compositions comprising the compounds and methods for their use and preparation are also provided.

NANOPARTICLE-BASED ABUSE-DETERRENT FORMULATIONS AND METHODS OF MAKING AND USING

Absstract of: WO2023069357A1

An abuse-deterrent formulation comprising an abuse-prone drug encapsulated in nanoparticles, a gel-forming polymer, and pharmaceutically acceptable excipients; method of use; and method of making.

IONIZABLE CATIONIC COMPOUND

Absstract of: WO2023067560A1

Novel ionizable lipid compounds of Formula I are provided. The use of the compounds in forming lipid nanoparticles is described. The lipid nanoparticles may encapsulate a therapeutic, such as a nucleic acid, and these may be used in the delivery of the therapeutic and in methods of treating certain conditions or for inducing an immune response.

IONIZABLE CATIONIC LIPID FOR MESSENGER RNA DELIVERY

Absstract of: WO2023067561A1

The use of an ionizable cationic lipid in forming lipid nanoparticles is described. The lipid nanoparticles may encapsulate a therapeutic, such as a nucleic acid, including conventional messenger RNA and self-amplifying messenger RNA, and may be used in the delivery of the therapeutic and in methods of treating certain conditions, or for inducing an immune response.

COMPOSITIONS AND METHODS OF THE DELIVERY OF ACTIVE AGENTS INCLUDING NUCLEIC ACIDS

Absstract of: AU2022371688A1

Disclosed herein are pH-sensitive nanoemulsions as well as methods of using thereof. These pH-sensitive nanoemulsions can comprise a lipid particle encapsulating an active agent. The lipid particle can comprise one or more ionizable lipids; one or more neutral lipids; one or more PEGylated lipids; and optionally one or more fusogenic oils. In some embodiments, these compositions can be buffered at an acidic pH (e.g., a pH of less than 6.5, such as a pH of from 4 to 6.5, or a pH of from 5.0 to 6.5). By buffering at an acidic pH, the delivery efficiency of the compositions can be enhanced as compared to otherwise identical compositions buffered at a pH of 7 or more.

AGGREGATE FORMED BY MEANS OF ASSEMBLING CHALCOGEN HETEROCYCLIC COMPOUND AND INSULIN, AND PREPARATION METHOD THEREFOR, AND INSULIN ORAL PREPARATION

Absstract of: EP4420680A1

Provided in the present invention are an aggregate and a preparation method therefor, and an insulin oral preparation. Specifically provided is an aggregate, which is an aggregate formed by means of assembling a chalcogen heterocyclic compound and insulin. The aggregate can be further prepared into an insulin oral preparation. The oral preparation can be used for reducing the blood glucose level of a mammal as part of a diabetes treatment regimen. The chalcogen heterocyclic compound in the insulin oral preparation prepared by means of the method can effectively protect insulin against the three physiological barriers of an oral uptake pathway, is stable in the gastrointestinal tract environment, is subjected to a dynamic chemical exchange reaction with intestinal mucin in intestinal juice and the sulfhydryl groups of proteins inside and outside an epithelial cell membrane by means of the molecular bond of polychalcogen on the surface, and enters the circulation system from the intestinal epithelial cell to achieve the effect of reducing blood glucose. When being orally administered, the insulin oral preparation has high bioavailability, has a good hypoglycemic effect in mammals, and can be used for treating diabetes.

NON-COVALENT BINDING PEPTIDE AND CARRIER COMPLEX COMPRISING IT

Absstract of: EP4420670A1

The invention relates to a positively charged peptide capable of non-covalently interact with negatively charged extracellular vesicles or nanoparticles. Said peptide is a fragment of the bacterial protein P40 and shows better interaction capabilities that the entire bacterial protein P40. The peptide of the invention can also be linked to a targeting element, such as targeting peptide, DNA aptamer, RNA aptamer, a protein, an antibody or a fragment thereof that binds to a target molecule, therefore it can be used for the targeted delivery of extracellular vesicles or nanoparticles further comprising a bioactive agent to a target cell, tissue or particle like a virus, that comprise the target molecule. Therefore, the present invention also relates to a carrier complex comprising the peptide of the invention non covalently bound to an extracellular vesicle or nanoparticle comprising a bioactive agent and its uses.

TREATMENT OF PRIMARY BILIARY CHOLANGITIS (PBC) WITH TOLERIZING NANOPARTICLES

Absstract of: AU2022371668A1

The present disclosure relates to methods of treating Primary Biliary Cholangitis (PBC) using tolerizing immune modifying nanoparticles encapsulating PBC associated antigens.

DRUG PRODUCT SURROGATE SOLUTIONS

Absstract of: WO2023069625A1

Provided herein are methods and compositions of a surrogate mRNA drug product. The surrogate mRNA drug product is made up of a physical property surrogate, a visual property surrogate, and a chemical property surrogate. The surrogate mRNA drug product has at least one quantitative or qualitative property such as viscosity, turbidity, density, and surface tension that is comparable to and matches the same property of a mRNA drug product comprised of mRNA in a lipid nanoparticle (LNP). The surrogate mRNA drug product, however, does not comprise mRNA or LNP.

MRNA VACCINE COMPOSITION

Absstract of: CA3235867A1

Disclosed herein are nucleic acid vaccine compositions including one or more polynucleotides encoding one or more antigenic polypeptide, formulated within a lipid reconstructed plant messenger packs (LPMPs) comprising natural lipids and an ionizable lipid. The disclosure also includes a method for making a nucleic acid vaccine, comprising reconstituting a film comprising purified PMP lipids in the presence of an ionizable lipid to produce a LPMP comprising the ionizable lipid, and loading into the LPMPs with one or more polynucleotides encoding one or more antigenic polypeptides.

POLYMERIC IMMUNO-NANOPARTICLES FOR TARGETED THERAPY AND DIAGNOSIS OF ATHEROSCLEROSIS

Absstract of: WO2023067488A1

A therapeutic composition for the treatment of atherosclerosis comprising immuno-nanoparticles of poly (lactic-co-glycolic) acid (PLGA) or the like conjugated with polyethylene glycol (PEG) or the like and engineered with immunoglobin-1 ( IUG-1) or the like, said immuno-nanoparticles encapsulating antioxidants and/or therapeutic proteins and/or specific inhibitors to be used in the targeted therapy of atherosclerotic pathology, such as active ingredients that determine the modulation of inflammation associated with atheromatous plaque. A drug delivery vector for the localized (in situ) treatment of atherosclerosis with the effect of reducing atherosclerotic plaque and imaging vector for the diagnosis of plaque instability in atherosclerosis.

EXTRACELLULAR VESICLES DERIVED FROM MILK AND PROCESS FOR ISOLATING THE SAME

Absstract of: AU2022374092A1

The present invention relates to the field of biotechnology, and particularly to milk derived extracellular vesicles, and provides a process for isolating such extracellular vesicles from milk and milk related fluids. The present invention is also related to compositions containing said extracellular vesicles derived from milk, particularly suitable for use in pharmaceutical, veterinary, cosmetic and/or nutraceutical applications.

A method for reducing the risk of coronary disease

Absstract of: GB2627637A

Provided herein is a lipid nanoparticle encapsulating a payload comprising one or more pharmaceutically active agents, for use in a method for reducing the risk of coronary disease; wherein the one or more pharmaceutically active agents comprise an mRNA encoding a gene editor and one or more guide RNAs, wherein the one or more guide RNAs are complementary to a segment of ANGPTL3 gene, and wherein the lipid nanoparticle further comprises a receptor targeting conjugate as defined herein.

一种共载鲁玛卡托-苦参碱干粉吸入剂及其制备方法

Absstract of: CN118542854A

本发明公开了一种共载鲁玛卡托‑苦参碱干粉吸入剂及其制备方法，涉及生物医药技术领域。本发明的共载鲁玛卡托‑苦参碱干粉吸入剂，由鲁玛卡托纳米粒、苦参碱和干粉载体材料混合制成；所述鲁玛卡托纳米粒由蛋白材料包载鲁玛卡托制备得到；所述蛋白材料包括牛血清白蛋白或丝素蛋白。本发明将鲁玛卡托和苦参碱共载入干粉微粒中，通过无创的方式吸入给药递送至肺部，使两药协同控制囊性纤维化的病症及其肺部炎症的并发症；本发明的共载鲁玛卡托‑苦参碱干粉吸入剂的制备方法工艺简单，制备效率高，可连续生产，满足大规模工业生产的需求。

用于表达IL-12和IL-1RA的组合物和方法

Absstract of: CA3240805A1

The present disclosure relates to the field of molecular virology, and particularly relates to nucleic acid molecules encoding a modified alphavirus virus viral genome or self-replicating RNA (srRNA) construct, pharmaceutical compositions containing the same, and the use of such nucleic acid molecules and compositions for production of desired products in cell cultures or in a living body. Also provided are methods for eliciting a pharmacodynamics effect in a subject.

一种靶向溶酶体的AIE光动力纳米颗粒及其制备方法和应用

Absstract of: CN118542940A

本发明公开一种靶向溶酶体的AIE光动力纳米颗粒及其制备方法和应用，制备方法包括以下步骤：S1.AIE光敏材料A1与F127聚醚在四氢呋喃中混合得到混合液，之后吹干得到胶层，向胶层中加入浓度为0.77‑0.93M的酸性水溶液，形成包裹有AIE光敏材料A1的F127胶束；S2.加入四乙氧基硅烷，搅拌0.5‑3小时，以上述F127胶束为模版，以四乙氧基硅烷为硅源，生成包裹有AIE光敏材料A1的二氧化硅纳米颗粒；S3.滴加氨丙基三乙氧基硅烷，搅拌22‑26小时，过滤，超滤离心9‑11分钟，制得表面带有氨基的二氧化硅纳米颗粒；S4.加入3‑(4‑吗啉基)丙基异硫氰酸酯，搅拌22‑26小时，经超滤离心得到AIE光动力纳米颗粒。本发明提及的制备方法简单，成本低，所得AIE光动力纳米颗粒A1@SiO2‑MP，具有较好的稳定性和生物相容性，能较好地富集于细胞溶酶体，经激发可生成活性氧对溶酶体实施氧化损伤，从而诱导细胞凋亡，具有较好的光动力治疗应用潜力。

一种单价及多价新型冠状病毒mRNA疫苗及其制备方法和用途

Absstract of: CN118542936A

本发明提供了一种单价及多价新型冠状病毒mRNA疫苗及其制备方法和用途。本发明的多价新型冠状病毒mRNA疫苗在BALB/c小鼠中作为初级免疫系列时，对多种SARS‑CoV‑2变体(包括原始毒株以及BA.1、BA.2.75、BA.4/5和XBB.1变体)诱导了更广泛的中和抗体反应。当BA.4/5二价疫苗作为异体增强剂接种于两剂灭活疫苗的初级疫苗接种系列后，即使在较低剂量下，也比灭活疫苗同源增强剂和组分单价疫苗诱导的中和抗体水平更高。因此，本发明多价mRNA疫苗可应用于SARS‑CoV‑2的临床对变种(VOCs)病毒的预防。

无定形光敏粒子、其制备方法及其使用方法

Absstract of: CA3231406A1

Amorphous nanoparticle compositions comprising a photosensitizer along with methods of making and using the same are provided. In particular, the amorphous nanoparticle compositions are generated and used in carrier-free, solubilizing agent-free applications to improve the photophysical and photochemical stability of clinically used photosensitizers, particularly verteporfin. The amorphous nanoparticle compositions may be used in fluorescence-guided surgery, photodynamic therapy of cancer and non-cancer diseases, fluorescence diagnosis of cancer and non-cancer diseases, blood-brain barrier opening, drug delivery to the brain, and/or in various other types of treatments and implementations.

超分子金属笼、水溶性纳米粒子及其制备方法与应用

Absstract of: CN118546177A

本发明公开了一种超分子金属笼、水溶性纳米粒子及其制备方法与应用。所述超分子金属笼的化学结构如式(Ⅰ)所示，其中所述金属笼由基于D‑A‑D型小分子光敏剂配体BTTP和配位夹角为90°的Pt(PEt3)2(OTf)2自组装制备得到，其中D‑A‑D型小分子光敏剂配体BTTP中引入三苯胺和吡啶供电子基团，使其能够引入聚集诱导发射效应，并且D‑A‑D型分子的构建，有利于促进吸收或发射波长的红移，使CNPs的吸收或发射范围延伸至NIR‑II。采用本发明的超分子金属笼C‑BTTP分子制备的水溶性纳米粒子具有近红外二区发射的能力、优秀的光热转换能力和光动力治疗效果，且在体外实验中，表现出良好的生物相容性和强的光毒性，作为光敏剂在生物成像和治疗上应用前景广阔。#imgabs0#

一种用于靶向治疗脑胶质瘤的药物及其制备方法与应用

Absstract of: CN118542848A

本申请属于生物医药技术领域，具体涉及一种用于靶向治疗脑胶质瘤的药物及其制备方法与应用。本申请通过将制备ICG/SN38纳米粒，一方面，能够干扰肿瘤细胞的DNA复制与修复，从而诱导肿瘤细胞凋亡；另一方面，ICG具有光学成像性能，对药物在体内的分布监测至关重要，此外ICG还展现出了一定程度的自然穿透血脑屏障的能力，为脑部疾病的诊断与治疗开辟了新的途径。进一步的，本申请通过将多肽修饰的巨噬细胞膜与ICG/SN38纳米粒融合，所获得的药物展现出了卓越的穿越血脑屏障性能及对脑胶质瘤的高度靶向性。这种设计不仅极大提高了治疗药物的递送效率，还显著降低了对健康脑组织的潜在影响，标志着在脑胶质瘤等中枢神经系统肿瘤治疗领域的一项重要进展。

一种氧化还原敏感植物多肽载药纳米颗粒及其制备方法

Nº publicación: CN118542846A 27/08/2024

Applicant:

武汉大学

Absstract of: CN118542846A

本发明涉及生物医用高分子的技术领域，具体涉及一种氧化还原敏感植物多肽载药纳米颗粒及其制备方法，以植物多肽为载体，引入氧化还原敏感结构，包载疏水性药物。本发明的植物多肽载药纳米颗粒具有氧化还原敏感响应能力，可在指定位置释放，降低药物对人体的毒性，提高药物的治疗效果。本发明的氧化还原敏感植物多肽载药纳米颗粒，可用于对疏水性药物的负载，以天然高分子为材料的载药纳米颗粒的制备，可以用于药物的控制释放，能够对特定氧化还原环境如癌细胞环境响应。本发明的制备方法操作简单，品质稳定，所制备载药纳米颗粒粒径可控，分散度集中，稳定性良好，适用于量产。